Extract

The primary objective of the study is to assess the safety of IV administration of rIX-FP. Safety will be evaluated by adverse events and laboratory changes over time. The secondary objective of the study is to evaluate the pharmacokinetics parameters, following a single intravenous dose of rIX-FP.

Inclusion criteria

• Hemophilia B

Country

• Austria
• France
• Germany
• Israel
• Italy
• Spain

Links

• nct
• ictrp